CSF3 and Miyoshi myopathy: In an Italian retrospective study in which patients with MM were treated with new agents (lenalidomide, carfilzomib, and daratumumab), the mobilization strategy with cyclophosphamide plus G-CSF and plerixafor “on demand” resulted in high success rate (95%) of autologous stem cell collections [61].